Pai Ganesh, Pai Anusha H
Derma-Care Skin and Cosmetology Centre, Mangalore, India.
Case Rep Dermatol. 2017 Aug 23;9(2):141-145. doi: 10.1159/000475519. eCollection 2017 May-Aug.
Psoriasis is a chronic, relapsing, inflammatory, immune-mediated systemic disease with mainly skin and joint manifestations. The available treatment options to cure psoriasis include topical therapy, phototherapy, and biological therapy. Biological therapy has become a promising option due to the rapid action and less adverse effects associated with its use. The newly developed biologic itolizumab is a humanized recombinant anti-CD6 monoclonal antibody of IgG1 isotype that binds to domain 1 of CD6, thereby immunomodulating human lymphocytes without interfering with the binding of CD6 to the activated leukocyte-cell adhesion molecule. In this case series, a total of 5 patients with chronic plaque psoriasis were treated with itolizumab. They exhibited a rapid PASI 75 response after 4 doses of itolizumab infusion. The patients were poor responders to methotrexate and/or cyclosporine therapy for a long time. All infusions were well tolerated by all patients with no adverse reactions or infections during the treatment period. Itolizumab can be a good option for management of psoriasis and psoriatic arthritis.
银屑病是一种慢性、复发性、炎症性、免疫介导的全身性疾病，主要表现为皮肤和关节症状。目前可用于治愈银屑病的治疗方法包括局部治疗、光疗和生物治疗。由于生物治疗起效迅速且副作用较少，已成为一种有前景的选择。新开发的生物制剂依妥珠单抗是一种IgG1同种型的人源化重组抗CD6单克隆抗体，它与CD6的结构域1结合，从而在不干扰CD6与活化白细胞黏附分子结合的情况下对人淋巴细胞进行免疫调节。在本病例系列中，共有5例慢性斑块状银屑病患者接受了依妥珠单抗治疗。在输注4剂依妥珠单抗后，他们迅速出现了达到PASI 75的反应。这些患者长期以来对甲氨蝶呤和/或环孢素治疗反应不佳。所有患者对所有输注耐受性良好，治疗期间无不良反应或感染。依妥珠单抗可能是治疗银屑病和银屑病关节炎的一个好选择。
